230 research outputs found
Spectral differences between the jets in `radio loud' and `radio quiet' hard state black hole binaries
We have compiled from the available literature a large set of radio
measurements of black hole binaries in the hard X-ray state for which
measurements of the gigahertz frequency radio spectral index are possible. We
separate the sample into `radio loud' and `radio quiet' subsets based upon
their distribution in the radio -- X-ray plane, and investigate the
distribution of radio spectral indices within each subset. The distribution of
spectral indices of the `radio loud' subset is well described by a Gaussian
distribution with mean spectral index and standard deviation
(here spectral index is defined such that a positive spectral index means
more flux at higher frequencies). The sparser sample for the `radio quiet'
subset can be approximated, less well, by a Gaussian with mean
and standard deviation ; alternatively the simple mean of the distribution
of the radio quiet subset is . The two spectral index distributions are
different at high statistical significance. Confirming previous work in the
literature, we test to see if the differences in observed spectra could result
from different distributions of jet viewing angles, but find no evidence for
this. We conclude therefore that the jets in the two groups are physically
different in some way, and briefly discuss possible origins and further
possible diagnostics. Finally we note that extrapolating to lower frequencies
the two subsets move closer together in the radio -- X-ray plane, and
approximately merge into a single distribution at around 400 MHz.Comment: Accepted for publication in MNRA
A Kriging procedure for processes indexed by graphs
International audienceWe provide a new kriging procedure of processes on graphs. Based on the construction of Gaussian random processes indexed by graphs, we extend to this framework the usual linear prediction method for spatial random fields, known as kriging. We provide the expression of the estimator of such a random field at unobserved locations as well as a control for the prediction error
Afshar's Experiment does not show a Violation of Complementarity
A recent experiment performed by S. Afshar [first reported by M. Chown, New
Scientist {\bf 183}, 30 (2004)] is analyzed. It was claimed that this
experiment could be interpreted as a demonstration of a violation of the
principle of complementarity in quantum mechanics. Instead, it is shown here
that it can be understood in terms of classical wave optics and the standard
interpretation of quantum mechanics. Its performance is quantified and it is
concluded that the experiment is suboptimal in the sense that it does not fully
exhaust the limits imposed by quantum mechanics.Comment: 6 pages, 6 figure
Recherche par une technique d'hémagglutination passive des traces sérologiques des principaux virus respiratoires des bovins et de Chlamydia psittaci dans un échantillon de la population des bovidés du Togo
D'après les résultats obtenus par la technique d'hémagglutination passive, le principal virus respiratoire des bovins du Togo est celui de la rhinotrachéite infectieuse bovine. Les autres virus et Chlamydia psittaci semblent avoir moins d'importanc
Recommended from our members
A feasibility randomised controlled trial of a motivational interviewing-based intervention for weight loss maintenance in adults
Background
Obesity has significant health and NHS cost implications. Relatively small reductions in weight have clinically important benefits, but long-term weight loss maintenance (WLM) is challenging. Behaviour change interventions have been identified as key for WLM. Motivation is crucial to supporting behaviour change, and motivational interviewing (MI) has been identified as a successful approach to changing health behaviours. The study was designed as an adequately powered, pragmatic randomised controlled trial (RCT); however, owing to recruitment issues, the study became a feasibility trial.
Objectives
To assess recruitment, retention, feasibility, acceptability, compliance and delivery of a 12-month intervention to support WLM. Secondary objectives were to assess the impact of the intervention on body mass index (BMI) and other secondary outcomes.
Design
Three-arm individually randomised controlled trial comprising an intensive arm, a less intensive arm and a control arm.
Setting
Community setting in South Wales and the East Midlands.
Participants
Individuals aged 18�70 years with a current or previous BMI of ??30 kg/m2 who could provide evidence of at least 5% weight loss during the previous 12 months.
Intervention
Participants received individually tailored MI, which included planning and self-monitoring. The intensive arm received six face-to-face sessions followed by nine telephone sessions. The less intensive arm received two face-to-face sessions followed by two telephone sessions. The control arm received a leaflet advising them on healthy lifestyle.
Main outcome measures
Feasibility outcomes included numbers recruited, retention and adherence. The primary effectiveness outcome was BMI at 12 months post randomisation. Secondary outcomes included waist circumference, waist-to-hip ratio, physical activity, proportion maintaining weight loss, diet, quality of life, health service resource usage, binge eating and well-being. A process evaluation assessed intervention delivery, adherence, and participants� and practitioners� views. Economic analysis aimed to assess cost-effectiveness in terms of quality-adjusted life-years (QALYs).
Results
A total of 170 participants were randomised. Retention was good (84%) and adherence was excellent (intensive, 83%; less intensive, 91%). The between-group difference in mean BMI indicated the intensive arm had BMIs 1.0?kg/m2 lower than the controls [95% confidence interval (CI) �2.2 kg/m2 to 0.2?kg/m2]. Similarly, a potential difference was found in weight (average difference of 2.8?kg, 95% CI �6.1 kg to 0.5?kg). The intensive arm had odds of maintaining on average 43% [odds ratio(OR) 1.4, 95% CI 0.6 to 3.5] higher than controls. None of these findings were statistically significant. Further analyses controlling for level of adherence indicated that average BMI was 1.2?kg/m2 lower in the intensive arm than the control arm (95% CI �2.5?kg/m2 to 0.0?kg/m2). The intensive intervention led to a statistically significant difference in weight (mean �3.7?kg, 95% CI �7.1?kg to �0.3?kg). The other secondary outcomes showed limited evidence of differences between groups. The intervention was delivered as planned, and both practitioners and participants were positive about the intervention and its impact. Although not powered to assess cost-effectiveness, results of this feasibility study suggest that neither intervention as currently delivered is likely to be cost-effective in routine practice.
Conclusion
This is the first trial of an intervention for WLM in the UK, the intervention is feasible and acceptable, and retention and adherence were high. The main effectiveness outcome showed a promising mean difference in the intensive arm. Owing to the small sample size, we are limited in the conclusions we can draw. However, findings suggest that the intensive intervention may facilitate long-term weight maintenance and, therefore, further testing in an effectiveness trial may be indicated. Research examining WLM is in its infancy, further research is needed to develop our understanding of WLM and to expand theory to inform the development of interventions to be tested in rigorously designed RCTs with cost-effectiveness assessed
Time-dependent visibility modelling of a relativistic jet in the X-ray binary MAXI J1803-298
Tracking the motions of transient jets launched by low-mass X-ray binaries
(LMXBs) is critical for determining the moment of jet ejection, and identifying
any corresponding signatures in the accretion flow. However, these jets are
often highly variable and can travel across the resolution element of an image
within a single observation, violating a fundamental assumption of aperture
synthesis. We present a novel approach in which we directly fit a single
time-dependent model to the full set of interferometer visibilities, where we
explicitly parameterise the motion and flux density variability of the emission
components, to minimise the number of free parameters in the fit, while
leveraging information from the full observation. This technique allows us to
detect and characterize faint, fast-moving sources, for which the standard time
binning technique is inadequate. We validate our technique with synthetic
observations, before applying it to three Very Long Baseline Array (VLBA)
observations of the black hole candidate LMXB MAXI J1803-298 during its 2021
outburst. We measured the proper motion of a discrete jet component to be
mas/hr, and thus we infer an ejection date of MJD
, which occurs just after the peak of a radio flare
observed by the Australia Telescope Compact Array (ATCA) and the Atacama Large
Millimeter/Sub-Millimeter Array (ALMA), while MAXI J1803-298 was in the
intermediate state. Further development of these new VLBI analysis techniques
will lead to more precise measurements of jet ejection dates, which, combined
with dense, simultaneous multi-wavelength monitoring, will allow for clearer
identification of jet ejection signatures in the accretion flow.Comment: 15 pages, 9 figures, 4 tables; Accepted for publication in MNRA
Disruption of PF4/H multimolecular complex formation with a minimally anticoagulant heparin (ODSH)
Recent studies have shown that ultra-large complexes (ULCs) of platelet factor 4 (PF4) and heparin (H) play an essential role in the pathogenesis of heparin-induced thrombocytopenia (HIT), an immune-mediated disorder caused by PF4/H antibodies. Because antigenic PF4/H ULCs assemble through non-specific electrostatic interactions, we reasoned that disruption of charge-based interactions can modulate the immune response to antigen. We tested a minimally anticoagulant compound (2-O, 3-O desulfated heparin, ODSH) with preserved charge to disrupt PF4/H complex formation and immunogenicity. We show that ODSH disrupts complexes when added to pre-formed PF4/H ULCs and prevents ULC formation when incubated simultaneously with PF4 and UFH. In other studies, we show that excess ODSH reduces HIT antibody (Ab) binding in immunoassays and that PF4/ODSH complexes do not cross-react with HIT Abs. When ODSH and unfractionated heparin (UFH) are mixed at equimolar concentrations, we show that there is a negligible effect on amount of protamine required for heparin neutralisation and reduced immunogenicity of PF4/UFH in the presence of ODSH. Taken together, these studies suggest that ODSH can be used concurrently with UFH to disrupt PF4/H charge interactions and provides a novel strategy to reduce antibody mediated complications in HIT
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
Background
Metastatic castration-resistant prostate cancer is enriched in DNA damage response (DDR) gene aberrations. The TOPARP-B trial aims to prospectively validate the association between DDR gene aberrations and response to olaparib in metastatic castration-resistant prostate cancer.
Methods
In this open-label, investigator-initiated, randomised phase 2 trial following a selection (or pick-the-winner) design, we recruited participants from 17 UK hospitals. Men aged 18 years or older with progressing metastatic castration-resistant prostate cancer previously treated with one or two taxane chemotherapy regimens and with an Eastern Cooperative Oncology Group performance status of 2 or less had tumour biopsies tested with targeted sequencing. Patients with DDR gene aberrations were randomly assigned (1:1) by a computer-generated minimisation method, with balancing for circulating tumour cell count at screening, to receive 400 mg or 300 mg olaparib twice daily, given continuously in 4-week cycles until disease progression or unacceptable toxicity. Neither participants nor investigators were masked to dose allocation. The primary endpoint of confirmed response was defined as a composite of all patients presenting with any of the following outcomes: radiological objective response (as assessed by Response Evaluation Criteria in Solid Tumors 1.1), a decrease in prostate-specific antigen (PSA) of 50% or more (PSA50) from baseline, or conversion of circulating tumour cell count (from ≥5 cells per 7·5 mL blood at baseline to <5 cells per 7·5 mL blood). A confirmed response in a consecutive assessment after at least 4 weeks was required for each component. The primary analysis was done in the evaluable population. If at least 19 (43%) of 44 evaluable patients in a dose cohort responded, then the dose cohort would be considered successful. Safety was assessed in all patients who received at least one dose of olaparib. This trial is registered at ClinicalTrials.gov, NCT01682772. Recruitment for the trial has completed and follow-up is ongoing.
Findings
711 patients consented for targeted screening between April 1, 2015, and Aug 30, 2018. 161 patients had DDR gene aberrations, 98 of whom were randomly assigned and treated (49 patients for each olaparib dose), with 92 evaluable for the primary endpoint (46 patients for each olaparib dose). Median follow-up was 24·8 months (IQR 16·7–35·9). Confirmed composite response was achieved in 25 (54·3%; 95% CI 39·0–69·1) of 46 evaluable patients in the 400 mg cohort, and 18 (39·1%; 25·1–54·6) of 46 evaluable patients in the 300 mg cohort. Radiological response was achieved in eight (24·2%; 11·1–42·3) of 33 evaluable patients in the 400 mg cohort and six (16·2%; 6·2–32·0) of 37 in the 300 mg cohort; PSA50 response was achieved in 17 (37·0%; 23·2–52·5) of 46 and 13 (30·2%; 17·2–46·1) of 43; and circulating tumour cell count conversion was achieved in 15 (53·6%; 33·9–72·5) of 28 and 13 (48·1%; 28·7–68·1) of 27. The most common grade 3–4 adverse event in both cohorts was anaemia (15 [31%] of 49 patients in the 300 mg cohort and 18 [37%] of 49 in the 400 mg cohort). 19 serious adverse reactions were reported in 13 patients. One death possibly related to treatment (myocardial infarction) occurred after 11 days of treatment in the 300 mg cohort.
Interpretation
Olaparib has antitumour activity against metastatic castration-resistant prostate cancer with DDR gene aberrations, supporting the implementation of genomic stratification of metastatic castration-resistant prostate cancer in clinical practice
A restricted spectrum of missense KMT2D variants cause a multiple malformations disorder distinct from Kabuki syndrome
Purpose: To investigate if specific exon 38 or 39 KMT2D missense variants (MVs) cause a condition distinct from Kabuki syndrome type 1 (KS1).
Methods: Multiple individuals, with MVs in exons 38 or 39 of KMT2D that encode a highly conserved region of 54 amino acids flanked by Val3527 and Lys3583, were identified and phenotyped. Functional tests were performed to study their pathogenicity and understand the disease mechanism.
Results: The consistent clinical features of the affected individuals, from seven unrelated families, included choanal atresia, athelia or hypoplastic nipples, branchial sinus abnormalities, neck pits, lacrimal duct anomalies, hearing loss, external ear malformations, and thyroid abnormalities. None of the individuals had intellectual disability. The frequency of clinical features, objective software-based facial analysis metrics, and genome-wide peripheral blood DNA methylation patterns in these patients were significantly different from that of KS1. Circular dichroism spectroscopy indicated that these MVs perturb KMT2D secondary structure through an increased disordered to É‘-helical transition.
Conclusion: KMT2D MVs located in a specific region spanning exons 38 and 39 and affecting highly conserved residues cause a novel multiple malformations syndrome distinct from KS1. Unlike KMT2D haploinsufficiency in KS1, these MVs likely result in disease through a dominant negative mechanism.This article is freely available via Open Access. Click on the Publisher URL to access it via the publisher's site.16-17/10/Newlife - The Charity for Disabled Children
FS/13/32/30069/BHF_/British Heart Foundation/United Kingdom
72160007/Chile's National Commission for Scientific and Technological Research
MR/K011154/1/MRC_/Medical Research Council/United Kingdom
WT_/Wellcome Trust/United Kingdompre-prin
- …